Search Results

Neural Network Surrogate Model Speeds Up Superconducting Magnet Simulation

Recently, a domestic research team has achieved an important breakthrough in the field of electromagnetic analysis and design of high-temperature superconducting magnets. The research paper "A Surrogate Model for High-Temperature Superconducting Magnets to Predict Current Distribution with Neural Networks," completed by Professor Qu Timing's team, has been officially accepted by the top journal in the superconductivity field, *Superconductivity*. This research innovatively introduces deep learning into the electromagnetic analysis of high-temperature superconducting magnets and successfully constructs a neural network-based surrogate model, providing a brand-new technical pathway for solving complex current distribution prediction and rapid optimization of magnet parameters...

2026-11-09

Think tank calls for European countries to form alliance to advance SMR deployment

Recently, the renowned think tank Clean Air Task Force (CATF) released a series of dedicated policy reports, noting that although Europe has improved its collaborative development of Small Modular Reactors (SMRs) compared with last year, governments are still significantly lagging behind technology developers in actual deployment actions, and there is an urgent need to form an alliance to pursue a deployment model based on unit clusters. Marina Qvist, head of CATF's advanced nuclear program, pointed out that current industry leadership is mainly in the hands of technology developers, who have determined through precise calculations that the commercial success of SMRs...

2026-11-07

France's Calogena Receives EU Funding to Build First SMR

Recently, French small modular reactor developer Calogena has secured €40 million (US$44.6 million) in funding through the European Commission's Innovation Fund to support the construction of its first commercial nuclear reactor in Pierrelatte, southern France. As a subsidiary of France's Gorgé Group, Calogena has been committed since its founding in 2021 to developing the CAL30 water-cooled small modular reactor, designed specifically to provide carbon-free energy for urban district heating networks. The reactor has a thermal power of 30 MWth and adopts a simple design based on a low-temperature, low-pressure pool-type reactor, offering extremely high safety and the ability to be reliably deployed near district heating networks...

2026-11-07

US Company Publishes Long-Term Safety Study of Targeted Radiopharmaceutical for Leukemia

Recently, a new American Society of Hematology (ASH) conference abstract has been developed from the long-term safety and tolerability study of Actimab-A combined with CLAG-M intensive salvage chemotherapy, focusing on the recovery of patients with relapsed or refractory acute myeloid leukemia after treatment. This progress extends the research focus from prior antitumor activity to long-term follow-up, supplementing data for continued development of the combination regimen. Actimab-A is an investigational targeted α therapy developed by Actinium Pharmaceuticals, composed of the antibody lintuzumab conjugated with actinium-225. This abstract involves follow-up of patients in a Phase I study who survived at least three months after treatment, with emphasis on analyzing blood cell count recovery and potential delayed renal and hepatic toxicity, in order to more comprehensively evaluate the safety profile after intensive treatment.

2026-11-05

Australian Company Finalizes Phase III Protocol for Brain Metastasis Imaging Radiopharmaceutical

Recently, Radiopharm Theranostics announced that it has received the final meeting minutes from the FDA End-of-Phase 2 meeting, during which both parties reached agreement on the design of the pivotal Phase III imaging trial for RAD101, advancing registration development preparations for this investigational radiopharmaceutical imaging agent. The study is planned as a single-arm, multicenter Phase III trial designed to enroll approximately 280 patients with previously irradiated brain metastases of indeterminate nature. The co-primary endpoints are the sensitivity and specificity of RAD101 PET relative to an established reference standard. RAD101 is labeled with Fluorine-18, and its development goal is to help identify brain metastasis lesions and improve the differentiation between tumor recurrence and treatment-related changes. Si...

2026-11-04

Russia Delivers First Steam Generator for MBIR Fast Neutron Research Reactor

Recently, the Podolsk Machine-Building Plant (ZiO-Podolsk), a subsidiary of Russia's State Atomic Energy Corporation (Rosatom), has officially completed the manufacture and delivery of the first of two steam generators for the Multipurpose Fast Neutron Research Reactor (MBIR). The unit is currently under intensive construction at the Research Institute of Atomic Reactors (NIIAR) in Dimitrovgrad, Ulyanovsk Oblast. It is reported that as the world's largest 150 MW sodium-cooled fast neutron research reactor of its kind, the MBIR employs a unique three-circuit heat transfer scheme and a counter-flow steam generator design, with its technology continuing and optimizing the experience from the BOR-60 reactor, which has been operating smoothly for decades. Each unit weighs 9 tonnes...

2026-11-04

The "Chain-Building" Lessons from Europe's Fusion Supply Chain: An Industrial Paradigm Leap from "Building Devices" to "Nurturing Chains"

When examining the global race toward commercializing controlled nuclear fusion, external attention is often drawn to record-breaking plasma temperatures, confinement times, and device scales. However, as the industry gradually enters the deep waters of transitioning from physics experiments to engineering construction, what ultimately determines whether parties can cross the commercialization chasm is often no longer merely theoretical breakthroughs in the laboratory, but rather the thickness of the industrial supply chain hidden behind the spotlight. Recently, Europe's "Fusion for Energy" organization (F4E, Fusion for Energy) officially released the research report "Building Europe's Fusion Supply Chain: 2007–2026." This report, which systematically reviews nearly two decades of construction history, discloses that through more than €7 billion...

2026-11-02

CNNC Atom High-Tech Sodium Iodide Capsules Supplied Directly to Macao for the First Time

Recently, sodium iodide [¹³¹I] capsules independently developed and produced by Atom High-Tech Co., Ltd., a subsidiary of China Isotope & Radiation Corporation under CNNC, successfully arrived at clinical frontlines in Macao, achieving the first stable supply of domestically produced sodium iodide [¹³¹I] capsules to Macao and completely filling the previous gap in Macao's lack of this clinical diagnostic and therapeutic service. It is understood that sodium iodide [¹³¹I] capsules are core radiopharmaceuticals widely used clinically for the diagnosis and treatment of thyroid diseases. Previously, Atom High-Tech had successfully achieved routine supply of short-half-life radiopharmaceuticals to Macao; the successful launch of this new product will strongly support Macao medical institutions in carrying out systematic radionuclide therapy and effectively reduce the burden of cross-border medical treatment on local patients.

2026-11-02

Startup "Marathon Fusion" Announces Transmutation of Mercury into Gold Using Thermonuclear Fusion Neutrons

Recently, San Francisco-based startup Marathon Fusion announced that it has successfully used high-energy neutrons produced by deuterium-tritium (D-T) thermonuclear fusion reactions to transmute the element mercury into gold, claiming that its yield reached ten times the previously recorded level at CERN. It is reported that the technology is based on high-energy neutrons released by D-T fusion reactions striking mercury-198 nuclei, stripping one neutron to convert them into the radioactive isotope mercury-197, which subsequently decays to ultimately form gold-197, the only stable isotope of gold. Marathon Fusion published gamma-ray spectroscopy as characteristic evidence for the presence of mercury-197; however, the specific mass of gold produced remains at...

2026-11-02

Exploring the Frontier of Advanced Fusion Physics: Physical Mechanisms and Engineering Challenges of D–³He Secondary Neutron Suppression under the Synergy of Hot Tails and Spin Polarization

In the process of controlled nuclear fusion advancing from theoretical exploration to commercial validation, the choice of fuel pathway has always been the core variable determining the engineering feasibility and economics of a reactor. For a long time, the deuterium–helium-3 (D–³He) reaction has been regarded as an ideal "low-neutron" ultimate fusion scheme because its primary products are only charged particles (helium-4 and high-energy protons), it does not directly produce neutrons, and it possesses the potential for direct energy conversion. However, under the traditional thermal equilibrium plasma framework, D–³He is not a truly neutron-free fuel. In October 2026, the U.S. Princeton Plasma Physics Laboratory (PP...

2026-10-31

China Spallation Neutron Source Completes Important Milestone Equipment Installation Task, Beam Power Exceeds 200 kW

To minimize the impact on user operations, the China Spallation Neutron Source Phase II Project (CSNS-II) utilizes the annual summer shutdown window to carry out Phase II equipment installation. During this year's summer shutdown, the project team completed the installation and commissioning of the front-end equipment of the linear accelerator, all solid-state modulators, and the third magnetic alloy cavity of the rapid cycling synchrotron. At this point, all equipment of the CSNS-II accelerator except the superconducting accelerator has been installed. After nearly a month of beam commissioning, on October 20, 2026, the facility's beam power exceeded 200 kW and officially entered user operation, reaching twice the Phase I design beam power. This is also an important milestone in the CSNS-II construction, providing key verification for achieving the Phase II...

2026-10-25

CNNC Hosts the 6th Radiopharmaceutical and Radionuclide Production Worker Vocational Skills Competition, Leveraging Shared Laboratories to Deepen Skilled Talent Cultivation

The 2026 6th CNNC Radiopharmaceutical and Radionuclide Production Worker Vocational Skills Competition, themed "Forging Craftsmanship with Nuclear Power, Winning the Future with Skills," was successfully held from October 20 to 24 at the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment. The competition was hosted by CNNC and organized by China Isotope & Radiation Corporation, and is a key practical measure for CNNC and the Nuclear and Radiation Safety Center to deepen strategic coordination and advance the construction of shared laboratories. The two sides closely focused on research directions including radiation environmental monitoring, nuclide analysis, and precise sample testing, promoting the co-construction and sharing of instruments and equipment, reference materials, methodology systems, and data platforms. A total of 16 units and 3...

2026-10-25

CGN Nuclear Technology Returns to the European Association of Nuclear Medicine Annual Congress, Hejia Isotopes Debut on the Global Nuclear Medicine Stage

The 39th Annual Congress of the European Association of Nuclear Medicine was held in Vienna, Austria, from October 17 to 21. CGN Nuclear Technology appeared once again, continuing its participation since its first exhibition in 2025, and showcased the core medical isotope products of CGN Isotope (Mianyang) Technology Co., Ltd. The exhibition focused on CGN Hejia® Germanium-68 solution, Germanium-Gallium generator and supporting automatic elution device, while also introducing multiple medical isotope products such as Oxygen-18, Copper-64, Zirconium-89 and Iodine-123. At this annual congress, physical exhibits such as the Germanium-Gallium generator and the supporting automatic elution device clearly demonstrated the company's technical...

2026-10-23

Southwest Supervision Station of the National Nuclear Safety Administration Conducts Demonstrative Supervision of Radiopharmaceuticals

Recently, the Southwest Nuclear and Radiation Safety Supervision Station of the Ministry of Ecology and Environment (National Nuclear Safety Administration), together with the Department of Radiation Source Safety Supervision, the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment, and Chengdu University of Technology, organized representatives of enterprises in its jurisdiction to conduct demonstrative supervision of radiopharmaceutical (medical isotope) production. This initiative aims to serve the national "Medium- and Long-Term Development Plan for Medical Isotopes (2021–2035)" and comprehensively enhance the radiation safety management level of the nuclear medical industry in the Southwest region. It is reported that this supervision activity practiced the concept of research-based supervision. In response to the characteristics of the Southwest region—where R&D, pilot testing, and large-scale production proceed in parallel, and the safety risks of unsealed radioactive materials are complex—the activity involved pre-arranging production processes...

2026-10-22

European Nuclear Medicine Congress Focuses on PET Nuclear Technology: Where Is the Boundary of Early Diagnosis

On October 19, 2026, at the plenary session of the European Association of Nuclear Medicine Congress (EANM 2026) held in Vienna, Austria, Professor Paola Anna Erba, President of the European Association of Nuclear Medicine, raised the major issue of when prevention is early enough. The conference held in-depth discussions on whether positron emission tomography (PET), a core nuclear medicine imaging technology, can detect cancer, cardiovascular disease, and Alzheimer's disease before symptoms appear. Regarding PET-based cancer screening in asymptomatic populations, Dr. Ken Herrmann of the University Hospital Essen in Germany clearly stated that currently, promoting fluorodeoxyglucose (FDG-PET)-based cancer screening in the general population is premature.

2026-10-20